Ironwood Pharmaceuticals IRWD announced that the FDA has approved the expanded use of its sole marketed drug, Linzess ...

The adult irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) segments remain ...

The FDA expanded its approval of linaclotide to include pediatric patients aged 2 to 5 years with functional ...

Linzess (linaclotide) is a prescription medication approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Most Medicare Part D plans provide coverage for the drug ...

Credit: Shutterstock. Linzess is a guanylate cyclase-C agonist. The Food and Drug Administration (FDA) has approved Linzess ® (linaclotide) for the treatment of functional constipation (FC) in ...

Inform your doctor of all medications, supplements, and health conditions that apply to you before taking Linzess to prevent possible interactions. Linzess may interact with antidiarrheal and ...

Phase 3 data support a lower age threshold for linaclotide, making it the first prescription therapy approved for functional constipation in patients ages 2 to 5.

Trulance (plecanatide) and Linzess (linaclotide) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat certain types of constipation. Trulance ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...

Linzess (linaclotide) is a prescription drug that’s used to treat certain kinds of constipation. The drug comes as an oral capsule. Linzess may be safe to take while pregnant or breastfeeding. Keep ...

Linzess is a prescription medication for adults that treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The typical dosage of Linzess for IBS-C is 290 ...